60 F
New York
Friday, May 7, 2021

Axovant [NASDAQ: AXGT] Inks AXO-LENTI-PD Supply Deal With Oxford Biomedica

Must read

Coinbase Pro Announces it will be Listing Internet Computer’s ICP

Coinbase Pro cryptocurrency exchange has disclosed that it has decided to list ICP once it goes live. ICP is the governance token of the...

WISeKey [NASDAQ: WKEY] Gets Investment to finance its TrustNFT.IO NFT Platform

WISeKey International Holding AG disclosed Friday that it has inked a term-sheet to enter into an unsecured short-term loan and the issuance and...

Moderna [NASDAQ: MRNA] Inks Supply Agreement with Switzerland

Moderna, Inc. disclosed that it has inked a supply agreement on Thursday with the Swiss Federal Government. As per the agreement, Moderna Inc...

TeraBlock Will Have its Own BSCPad IDO Soon

TeraBlock which is a project making a platform for automated cryptocurrency portfolio management disclosed that it is preparing for an initial DEX offering (IDO)...

Axovant Gene Therapies Ltd. [NASDAQ: AXGT] disclosed today that its subsidiary has inked a three-year Clinical Supply Agreement (CSA) with Oxford Biomedica Plc [LSE: OXB].

The CSA between the two firms in June 2018 for a worldwide licensing agreement for the Parkinson’s disease gene therapy program OXB-102, now called AXO-Lenti-PD. AXO-Lenti-PD is an investigational gene therapy developed for the treatment of Parkinson’s disease.

As per the deal, to continue the ongoing and future clinical development of AXO-Lenti-PD Oxford Biomedica will make GMP batches for AXGT. Axovant Gene Therapies is currently directing the SUNRISE-PD phase 2 Trial with AXO-Lenti-PD.

Shares of Axovant had traded up 0.34% and up +0.01 during the trading of Thursday. It has a day low range of $2.93 and a day high range of $3.03. If we look at its liquidity, the quick ratio for Axovant Gene Therapies is 2.70. Similarly, its current ratio is the same as the quick ratio.

Continuing to look at its profitability, its return on assets (ROA) is -92.70% and return on equity (ROE) is -257.10%. Axovant has reported the income of -72.60 million. It has total market capitlization of 125.79 million.

During the period of 52-week, this company’s stocks have fluctuated between the low of $1.41 and a high of $8.08. It has increased 112.06% from its 52-weeks low and moved down -63.00% from its 52-weeks high. Axovant is looking forward to work with Oxford Biomedica for the development of AXO-Lenti-PD.

More articles

Latest article

Why Chiasma [NASDAQ: CHMA] Stock is Skyrocketed?

Shares of Chiasma, Inc. surged 46.48% during the trading session of Wednesday. Chiasma has disclosed the financial results for the Q1 completed March...

NeoGenomics [NASDAQ: NEO] Announces Acquisition of Inivata Ltd

NeoGenomics, Inc. revealed Wednesday that it has decided to purchase Inivata Ltd. Inivata will grow into a liquid biopsy-centered division together with increasing...

R1 RCM [NASDAQ: RCM] Announces Acquisition of VisitPay

R1 RCM Inc. disclosed Tuesday that it has decided to purchase VisitPay. The firm has inked an agreement to buy VisitPay for nearly...

Binance Coin Makes History as its Market Cap Reach $100 Billion

The market capitalization of Binance set new records as the exchange token of Binance and the native asset of Binance Smart Chain (BSC) touched...

Precipio [NASDAQ: PRPO] Roll Out Rapid COVID-19 Antibody test on Amazon Platform

Shares of Precipio, Inc. skyrocketed 40.35% during the trading session of Monday. The strong performance of the firm has highlighted the positive sentiments...

TechX Ink Deal to Buy Fiat-to-Crypto Merchant Services Gateway XPort Digital

TechX Technologies Inc disclosed Monday that it has bought fiat-to-crypto merchant services gateway XPort digital. The firm has bought a 100% stake in XPort...

Lockheed [NYSE: LMT] Present F-35 Best and Final Offer to Finnish Government

Lockheed Martin Corporation disclosed that it has presented F-35 best and final offer (BAFO) on April 29, 2021, to the Finnish government. It...

Clene [NASDAQ: CLNN] Gets Two Patent Notice of Allowances

Clene Inc. disclosed that Clene Nanomedicine, Inc. U.S. Patent and Trademark Office has provided Notices of Allowance for two significant patent applications. Clene...